IMBRUVICA Drug Patent Profile

When do Imbruvica patents expire, and when can generic versions of Imbruvica launch?

Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. There are fifty-seven patents protecting this drug and four Paragraph IV challenges.

This drug has five hundred and eight patent family members in fifty countries.

The generic ingredient in IMBRUVICA is ibrutinib. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ibrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Imbruvica

Imbruvica was eligible for patent challenges on November 13, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2034. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are six tentative approvals for the generic drug (ibrutinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for IMBRUVICA

International Patents:	508
US Patents:	57
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	151
Patent Applications:	5,809
Drug Prices:	Drug price information for IMBRUVICA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMBRUVICA
What excipients (inactive ingredients) are in IMBRUVICA?	IMBRUVICA excipients list
DailyMed Link:	IMBRUVICA at DailyMed

See drug prices for IMBRUVICA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IMBRUVICA

Constraining patent/regulatory exclusivity:

9,296,753*PED

NDA:

205552

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

12,201,690

NDA:

217003

Dosage:

SUSPENSION;ORAL

Constraining patent/regulatory exclusivity:

9,655,857*PED

NDA:

210563

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IMBRUVICA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Peter MacCallum Cancer Centre, Australia	Phase 2
Oncternal Therapeutics, Inc	Phase 3
Academic and Community Cancer Research United	Phase 2

See all IMBRUVICA clinical trials

Pharmacology for IMBRUVICA

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for IMBRUVICA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMBRUVICA	Capsules	ibrutinib	70 mg	205552	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	280 mg and 420 mg	210563	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	560 mg	210563	1	2018-11-05
IMBRUVICA	Capsules	ibrutinib	140 mg	205552	8	2017-11-13

US Patents and Regulatory Information for IMBRUVICA

IMBRUVICA is protected by eighty-eight US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,296,753.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes	10,751,342*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		DISCN	Yes	No	10,751,342*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes	8,703,780*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	SUSPENSION;ORAL	217003-001	Aug 24, 2022		RX	Yes	Yes	9,801,883
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes	9,296,753*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes	11,672,803
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	10,751,342*PED				Y

EU/EMA Drug Approvals for IMBRUVICA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Imbruvica	ibrutinib	EMEA/H/C/003791IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.	Authorised	no	no	no	2014-10-21

International Patents for IMBRUVICA

When does loss-of-exclusivity occur for IMBRUVICA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Guatemala

Hong Kong

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMBRUVICA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011261185	The use of inhibitors of Bruton's tyrosine kinase (Btk)
Australia	2015275321	The use of inhibitors of Bruton's tyrosine kinase (Btk)
Australia	2018204179	The use of inhibitors of Bruton's tyrosine kinase (Btk)
Australia	2020202752	The use of inhibitors of Bruton's tyrosine kinase (Btk)
Australia	2022201741	The use of inhibitors of Bruton's tyrosine kinase (Btk)
Australia	2022201742	The use of inhibitors of Bruton's tyrosine kinase (Btk)
Australia	2022201972	The use of inhibitors of Bruton's tyrosine kinase (Btk)

Supplementary Protection Certificates for IMBRUVICA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2201840	C300728	Netherlands		PRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021
2201840	CA 2015 00021	Denmark		PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141021
2201840	PA2015017	Lithuania		PRODUCT NAME: IBRUTINIBUM; REGISTRATION NO/DATE: EU/1/14/945 20141021
2201840	C20150014 00145	Estonia		PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
2201840	15C0029	France		PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
2201840	92692	Luxembourg		PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER: EU/1/14/945
2201840	1590021-0	Sweden		PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/14/945, 2014-10-23; DEN 14 APRIL 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 1890047-2 1590021-0 2290012-0 1490008-8 1890006-8 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.

IMBRUVICA (ibrutinib) market dynamics and financial trajectory: revenue drivers, exclusivity clock, competitive pressures, and next-cycle risk

Last updated: July 22, 2026

IMBRUVICA (ibrutinib) is a long-duration oncology revenue franchise driven by durable responses in CLL/SLL and mantle cell lymphoma (MCL), with growth anchored by continued frontline and combination adoption in CLL. Financial trajectory is increasingly shaped by three forces: (1) patent and exclusivity timing that governs generic and biosimilar risk for ibrutinib, (2) competitive displacement from next-generation BTK inhibitors and updated guideline positioning, and (3) payer and sequencing pressure as newer regimens spread and as combination strategies mature.

How much revenue did IMBRUVICA generate and what is the financial trajectory vs peers?

IMBRUVICA is a multi-indication BTK inhibitor commercial platform. Industry-wide dynamics in 2020-2024 shifted oncology spend toward fixed-duration and combination regimens, but ibrutinib’s staying power came from long-term disease control in CLL and MCL and from the depth of clinical data across lines of therapy.

Core commercial shape (high level):

• Sustained CLL/SLL demand: continuing uptake where ibrutinib remains a preferred option due to response durability and combination fit.
• MCL stabilization then pressure: MCL demand depends on line-of-therapy placement and payer preference amid alternate BTK inhibitors and non-BTK regimens.
• Oncology buy-downs: payer contracting, dose optimization, and patient access programs tend to smooth declines but do not halt volume contraction when label guidance shifts.

Peer context that matters financially:

• Next-generation BTK inhibitors (including acalabrutinib, zanubrutinib, and pirtobrutinib) compete on tolerability, dosing schedule, and head-to-head and cross-trial efficacy framing.
• The BTK class shows “share transfer” patterns rather than category collapse. IMBRUVICA’s revenue trajectory therefore tracks both clinical preference and institutional formulary behavior more than incidence growth.

What segment mix drives IMBRUVICA sales?

The sales base is primarily:

• CLL/SLL (frontline and relapsed/refractory use)
• Mantle cell lymphoma (relapsed/refractory use in key geographies)
• Additional hematologic uses vary by label and country-specific uptake, but CLL/SLL and MCL are the dominant revenue anchors.

How do patient flow and adherence affect revenue?

• Ibrutinib is continuous therapy. Revenue is sensitive to discontinuation rates due to AEs and comorbidities, but also benefits from “stay-on-drug” behavior when responses persist.
• Real-world persistence is a key driver of the slope of revenue changes, especially when competitors offer fixed-duration strategies or improved tolerability that reduces drop-off.

What market dynamics are shaping IMBRUVICA adoption and share?

Adoption is guided by:

1. Guideline sequencing and label interpretation in CLL and MCL.
2. Real-world tolerability relative to next-generation BTK inhibitors.
3. Payer access design including step therapy, prior authorization thresholds, and rebates.
4. Combination strategy maturity: how payers and oncologists integrate ibrutinib into chemoimmunotherapy-free and regimen-combination pathways.

How do newer BTK inhibitors change IMBRUVICA’s competitive position?

Next-gen BTK inhibitors pressure IMBRUVICA via three routes:

• Safety profile preference: lower rates of certain AEs influence formulary placement and physician choice.
• Convenience: dosing schedule and management burden affect switching.
• Mechanism of resistance narratives: sequential therapy post-ibrutinib failure can shift patients toward alternatives.

In practical market terms, competition does not erase IMBRUVICA’s base quickly. It narrows new patient starts and increases switching, which gradually erodes growth and raises the slope of declines once new patient cohorts become smaller.

What role do combinations play in demand?

Combination regimens can extend use by improving depth of response and maintaining “stay” behavior. But they also create substitution risk because combinations may be built around whichever BTK inhibitor is easiest to access under payer contracts. As combination landscapes stabilize, payer contracting becomes the primary determinant of which BTK inhibitor captures regimen share.

What payer and reimbursement trends affect revenue?

• Increased utilization management in oncology, including prior authorization and restricted formularies.
• Preference for regimens that reduce overall cost-per-response, even if drug acquisition cost is higher.
• Banding of BTK inhibitor coverage to reduce exposure to discontinuation-prone patients, which can shift net effective usage.

When does IMBRUVICA face exclusivity and generic risk?

A drug’s financial trajectory in branded oncology is strongly governed by exclusivity and patent estate durability, because it determines how long the manufacturer can sustain pricing power and market share without generic entry shocks.

Key commercial risk categories:

• Patent expiration risk: governs whether ANDA/entry is possible for small-molecule ibrutinib.
• Method-of-use and formulation patent coverage: governs whether generics can be marketed for specific dosing regimens or indications even if the base active becomes less protected.
• Orange Book listing strategy: determines practical launch windows for generic and authorized generic behavior.

What patent estate factors typically control the entry window for ibrutinib?

For a branded small molecule, the entry timeline generally depends on:

• Whether patents tied to key indications (CLL, MCL) remain in force.
• Whether the Orange Book has unexpired patents that prevent “same indication” approval.
• Whether litigation settlements constrain entry timelines through agreed design-arounds or launch triggers.

How does litigation usually alter the generic timeline?

In branded small-molecule oncology, Paragraph IV suits often trade:

• Delay payments or market-entry holdbacks (direct or indirect)
• Carve-outs by dosage strength or indication
• Timed settlements that define the first launch date even if some patents expire earlier

IMBRUVICA’s revenue sensitivity is therefore not only to patent expiry dates, but also to whether litigation produced settlements that effectively “extend” the launch window.

What is the Orange Book status of IMBRUVICA and which patents protect the franchise?

The Orange Book is the operative list for US regulatory and litigation timing for ibrutinib. The number, type, and remaining term of patents listed for:

• drug substance
• drug product
• formulations
• methods of use determines the practical risk window for generic entry.

How many patent layers typically matter for IMBRUVICA?

For a mature branded oncology asset, protection typically spans:

• Composition-of-matter and key process patents (substance/product)
• Formulation patents for dosage form and stability
• Method-of-use patents tied to dosing schedules and indications
• Continuation filings that extend some claim scopes

For investors and litigators, the operational question is which Orange Book patents remain unexpired as the key “first potential launch date” approaches.

What Paragraph IV generic challenges affect IMBRUVICA?

Generic entry pressure in small-molecule oncology typically comes via:

• ANDA filers seeking approval for one or more indications
• Paragraph IV certification against Orange Book patents
• Litigation and settlement that impacts launch timing

The financial trajectory implication is direct: even when patents expire, generic entry timing and “authorized generic” dynamics can compress price erosion and accelerate revenue decline.

What is the generic entry risk for ibrutinib?

Generic entry risk is typically concentrated in:

• Indications with the thickest patent defenses expiring first
• Strengths and dosage forms with fewer formulation barriers
• Scenarios where method-of-use patents are design-around-able or where settlement agreements enable earlier entry

How does biosimilar risk apply to IMBRUVICA?

IMBRUVICA is a small-molecule therapy (ibrutinib), so biosimilar risk is not applicable in the same framework as biologics. The relevant exclusivity threat is generic small-molecule entry under ANDA.

How strong is the patent estate for IMBRUVICA?

For a franchise with long clinical adoption, the patent estate strength is assessed by:

• Remaining term of Orange Book-listed patents
• Breadth of claim coverage in key dosage strengths and indications
• Litigation history and the presence of settlements
• Continuation patent strategy that extends certain claim scopes

IMBRUVICA’s financial durability has historically depended on the ability to keep key indications protected from generic substitution long enough to preserve pricing.

How does IMBRUVICA compare with other BTK inhibitors commercially?

IMBRUVICA vs acalabrutinib, zanubrutinib, and pirtobrutinib: what drives share shift?

The revenue impact usually follows a consistent market pattern:

• improved tolerability and dosing convenience drive switch among CLL patients
• subsequent-line positioning influences how much incremental volume flows to each BTK inhibitor
• competitive head-to-head or cross-trial interpretations drive physician preference and formulary decisions

Commercial translation:

• IMBRUVICA’s revenue trajectory is most threatened where competitor contracts win frontline or early-line cohorts.
• IMBRUVICA can retain value longer where it remains entrenched in established lines and where physician familiarity and real-world management experience reduce switching.

What indications contribute most to downside risk for IMBRUVICA revenue?

Revenue erosion risk rises when:

• frontline or favored-line recommendations shift toward newer BTK inhibitors
• payer policies narrow access to IMBRUVICA versus alternatives
• generic entry becomes feasible for the dominant indications

CLL/SLL downside pathways

• Competitor BTK inhibitors displacing new starts
• Combination regimen contracting shifting away from ibrutinib
• Future availability of lower-cost alternatives if patent barriers weaken

MCL downside pathways

• Second- and later-line treatment mix shifting to other BTK options and non-BTK platforms
• Increased use of fixed-duration and chemo-free alternatives where tolerability or patient convenience matters more for payer coverage

What is IMBRUVICA’s manufacturing and IP barrier profile?

For small molecules, IP barriers manifest through:

• process patents that complicate cost-effective generic manufacturing
• formulation patents that affect stability or dissolution characteristics
• method-of-use patents that can constrain label entry for generics

Manufacturing scale typically supports both branded and generic production, so cost and legal timing are decisive rather than capacity constraints.

How do revenue exposure and pricing dynamics evolve after generic entry?

When small-molecule generics enter:

• pricing typically collapses quickly through wholesale and contracting channels
• volume can be slower to switch if physician practice lags or if patient subgroups have clinical/administrative barriers
• authorized generics can compress the depth and timing of price erosion, but reduce branded market share nonetheless

For IMBRUVICA, financial trajectory is therefore a function of:

• whether generic entry occurs across all dominant indications simultaneously
• whether brand retains limited-use protection via method-of-use patents or label carve-outs
• whether payer contracts lock in generics quickly

Key Takeaways

• IMBRUVICA’s financial trajectory is driven by durable CLL/SLL and MCL demand, but share is increasingly determined by payer contracting and tolerability-driven switching toward next-generation BTK inhibitors.
• Exclusivity and the Orange Book patent stack determine the real generic shock timeline, with settlements and method-of-use coverage often shaping practical launch dates.
• The dominant financial risk is not biological replacement but small-molecule generic substitution and indication-level label vulnerability as patents expire or are neutralized through litigation outcomes.
• Commercial pressure intensifies through reduced new patient starts rather than abrupt category collapse, making the revenue slope sensitive to frontline guideline and formulary shifts.

FAQs

1. What factors most influence IMBRUVICA share loss in CLL?
   Guideline positioning for frontline therapy, payer access rules, and tolerability-based switching to next-generation BTK inhibitors.

2. How does an Orange Book method-of-use patent affect generic competition for ibrutinib?
   It can delay label-level generic substitution for protected indications or regimens even when some substance-level protection weakens.

3. What pricing and volume pattern typically follows generic entry of a branded small-molecule oncology drug?
   Rapid price erosion with a slower volume adjustment depending on physician and payer switching speed, plus possible authorized generic effects.

4. Does biosimilar competition pose a risk to IMBRUVICA?
   No, IMBRUVICA is a small molecule; the relevant competition is generic entry under ANDA.

5. Which competitive mechanism most threatens IMBRUVICA’s incremental growth?
   Contracts that steer new patients toward alternative BTK inhibitors for early-line therapy and combination regimens.

References

1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (IMBRUVICA, ibrutinib). FDA.
2. FDA. Drug Approval Package for IMBRUVICA (ibrutinib). FDA.

DrugChatter Q&A for IMBRUVICA

Earliest generic entry date imbruvica?
Singapore imbruvica ibrutinib?
Imbruvica online pharmacy?
Imbruvica patent expiry date?
Buy imbruvica online india?